We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.30 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.77%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.41%.
DGX’s Q4 Estimates
For the fourth quarter of 2024, the Zacks Consensus Estimate for Quest Diagnostics’ revenues is pegged at $2.57 billion, indicating an increase of 12.4% from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s fourth-quarter 2024 EPS suggests a 1.9% increase to $2.19.
Estimate Revision Trend Ahead of DGX’s Q4 Earnings
Estimates for Quest Diagnostics’ Q4 earnings have remained constant at $2.19 in the past 60 days.
Here’s a quick recap of the company’s performance leading up to this announcement.
Factors Likely to Influence DGX’s Q4 Performance
We anticipate impressive growth in the company’s Diagnostic Information Services (“DIS”) in the fourth quarter of 2024, driven by strong performances across the core physician and hospital channels. In physician lab services, Quest Diagnostics is likely to have benefited from new customer wins and expanded business, mainly due to the increased utilization of Advanced Diagnostics services. The company’s investments in these highly specialized offerings continue to scale innovations to improve patient care and drive growth.
Continuing the recent momentum, several clinical areas are likely to have delivered robust revenues in the fourth quarter. Brain health area growth may have been driven by the AD-Detect blood-based Alzheimer’s disease testing. In molecular genomics and oncology, DGX is likely to advance the broad national launch of the Haystack MRD (molecular residual disease) blood test. Women’s health revenues are likely to have been supported by strong demand for prenatal and hereditary genetic testing, as well as genital tract infections, including several STIs (sexually transmitted infections). The company may have witnessed high demand for tests that help physicians comprehensively screen for autoimmune disorders to speed diagnosis and expedite specialized care.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics’ string of acquisitions is also expected to have bolstered its performance in the to-be-reported quarter. The company completed the acquisition of select laboratory assets from OhioHealth in October 2024 and Alina Health the month before. The addition of LifeLabs may have helped the company grow in the Canadian market, which offers more favorable demographics than the United States.
Quest Diagnostics’ fourth-quarter top line is also expected to have been boosted by strong Medicare Advantage volume and revenue growth, as these plans focus on directing testing to high-quality, cost-efficient options like the company. It is likely to have continued to expand into new geographies through partnerships with health plans.
In Hospital lab services, the persistent staffing challenges for hospitals to fill specialized lab positions may have continued to drive robust demand for the reference testing business. The dynamic is prompting hospitals to take advantage of Quest Diagnostics’ expanding advanced diagnostics portfolio rather than building their in-house capabilities. The expansion of consumer-initiated tests on questhealth.com is likely to have generated strong revenues, along with an impressive repeat customer rate in the fourth quarter.
Going by our model, the company’s DIS revenues are likely to increase 11.7% year over year in the to-be-reported quarter.
Operationally, Quest Diagnostics’ strategic use of automation and AI is likely to have played a key role in improving quality, service, efficiency and the workforce experience. Recent developments, such as the launch of the highly automated laboratory in Lenexa, KS, piloting of automated specimen accessioning in the Clifton lab, and the collaboration with Hologic to incorporate their AI-driven cytology solution are expected to have favorably boosted the performance in the fourth quarter of 2024. Finally, the company’s Invigorate program is expected to have met its targeted 3% in annual cost savings.
Our model projects Quest Diagnostics’ operating income and EBITDA (both on a non-GAAP basis) to improve by 20.7% and 20.1%, respectively, in the fourth quarter of 2024 compared to the last year.
What Our Model Unveils for DGX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Quest Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.10%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS is expected to increase 14.4% from the year-ago quarter figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is slated to release fourth-quarter 2024 results on Feb. 25.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.42%. The Zacks Consensus Estimate for Merit Medical’s fourth-quarter EPS is expected to increase by 2.47% from the year-ago quarter figure.
Exelixis (EXEL - Free Report) has an Earnings ESP of +2.99% and a Zacks Rank #2. The company is expected to release fourth-quarter fiscal 2024 results on Feb. 4.
The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 26.52%. The Zacks Consensus Estimate for EXEL’s fourth-quarter EPS is expected to surge 51.5% from the year-ago reported figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?
Quest Diagnostics (DGX - Free Report) is set to release its fourth-quarter 2024 results on Jan. 30 before the market opens.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.30 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.77%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.41%.
DGX’s Q4 Estimates
For the fourth quarter of 2024, the Zacks Consensus Estimate for Quest Diagnostics’ revenues is pegged at $2.57 billion, indicating an increase of 12.4% from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s fourth-quarter 2024 EPS suggests a 1.9% increase to $2.19.
Estimate Revision Trend Ahead of DGX’s Q4 Earnings
Estimates for Quest Diagnostics’ Q4 earnings have remained constant at $2.19 in the past 60 days.
Here’s a quick recap of the company’s performance leading up to this announcement.
Factors Likely to Influence DGX’s Q4 Performance
We anticipate impressive growth in the company’s Diagnostic Information Services (“DIS”) in the fourth quarter of 2024, driven by strong performances across the core physician and hospital channels. In physician lab services, Quest Diagnostics is likely to have benefited from new customer wins and expanded business, mainly due to the increased utilization of Advanced Diagnostics services. The company’s investments in these highly specialized offerings continue to scale innovations to improve patient care and drive growth.
Continuing the recent momentum, several clinical areas are likely to have delivered robust revenues in the fourth quarter. Brain health area growth may have been driven by the AD-Detect blood-based Alzheimer’s disease testing. In molecular genomics and oncology, DGX is likely to advance the broad national launch of the Haystack MRD (molecular residual disease) blood test. Women’s health revenues are likely to have been supported by strong demand for prenatal and hereditary genetic testing, as well as genital tract infections, including several STIs (sexually transmitted infections). The company may have witnessed high demand for tests that help physicians comprehensively screen for autoimmune disorders to speed diagnosis and expedite specialized care.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics Incorporated price-eps-surprise | Quest Diagnostics Incorporated Quote
Quest Diagnostics’ string of acquisitions is also expected to have bolstered its performance in the to-be-reported quarter. The company completed the acquisition of select laboratory assets from OhioHealth in October 2024 and Alina Health the month before. The addition of LifeLabs may have helped the company grow in the Canadian market, which offers more favorable demographics than the United States.
Quest Diagnostics’ fourth-quarter top line is also expected to have been boosted by strong Medicare Advantage volume and revenue growth, as these plans focus on directing testing to high-quality, cost-efficient options like the company. It is likely to have continued to expand into new geographies through partnerships with health plans.
In Hospital lab services, the persistent staffing challenges for hospitals to fill specialized lab positions may have continued to drive robust demand for the reference testing business. The dynamic is prompting hospitals to take advantage of Quest Diagnostics’ expanding advanced diagnostics portfolio rather than building their in-house capabilities. The expansion of consumer-initiated tests on questhealth.com is likely to have generated strong revenues, along with an impressive repeat customer rate in the fourth quarter.
Going by our model, the company’s DIS revenues are likely to increase 11.7% year over year in the to-be-reported quarter.
Operationally, Quest Diagnostics’ strategic use of automation and AI is likely to have played a key role in improving quality, service, efficiency and the workforce experience. Recent developments, such as the launch of the highly automated laboratory in Lenexa, KS, piloting of automated specimen accessioning in the Clifton lab, and the collaboration with Hologic to incorporate their AI-driven cytology solution are expected to have favorably boosted the performance in the fourth quarter of 2024. Finally, the company’s Invigorate program is expected to have met its targeted 3% in annual cost savings.
Our model projects Quest Diagnostics’ operating income and EBITDA (both on a non-GAAP basis) to improve by 20.7% and 20.1%, respectively, in the fourth quarter of 2024 compared to the last year.
What Our Model Unveils for DGX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Quest Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Masimo (MASI - Free Report) has an Earnings ESP of +4.05% and a Zacks Rank #2. The company is set to release fourth-quarter 2024 results on Feb. 25. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.10%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS is expected to increase 14.4% from the year-ago quarter figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is slated to release fourth-quarter 2024 results on Feb. 25.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.42%. The Zacks Consensus Estimate for Merit Medical’s fourth-quarter EPS is expected to increase by 2.47% from the year-ago quarter figure.
Exelixis (EXEL - Free Report) has an Earnings ESP of +2.99% and a Zacks Rank #2. The company is expected to release fourth-quarter fiscal 2024 results on Feb. 4.
The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 26.52%. The Zacks Consensus Estimate for EXEL’s fourth-quarter EPS is expected to surge 51.5% from the year-ago reported figure.